Building the Future of Cancer T Cell Immunotherapy

CAR/TCR Technology

Latest News

Collaboration

eACT™ (engineered Autologous Cell Therapy) is a promising innovation in immunotherapy encompassing T cells manufactured ex vivo, that are genetically redirected against cancerous cells.  

eACT™ unleashes and focuses the full potential of the immune system against cancer, under the paradigm of personalized medicine.

April 14, 2014

Kite Pharma Expands Leadership Team and Announces Senior Management Promotions

April 11, 2014
Kite Pharma Expands Company's Board of Directors with the Appointment of Jonathan M. Peacock
April 2 2014
Kite Pharma Announces the Appointment of Arie Belldegrun, M.D., as President and Chief Executive Officer

Kite Pharma is partnered with the National Cancer Institute (NCI) through a Cooperative Research and Development Agreement (CRADA).